High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in P… (NCT05268887) | Clinical Trial Compass
RecruitingNot Applicable
High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease
United States40 participantsStarted 2022-02-09
Plain-language summary
Parkinson's disease (PD) impacts different types of neural oscillations in the brain, including beta (13-30Hz) and gamma oscillations (30-80Hz), which contributes to PD's cardinal symptoms of resting tremor, rigidity, bradykinesia (slowness of movement), and gait instability. The investigators' lab has developed a non-invasive method of increasing gamma power in the brain using Gamma Entrainment Using Sensory Stimulation (GENUS) through light, sound, and tactile stimulation devices. For this study, 40 participants with mild Parkinson's disease will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) before, during, and after light, sound, and tactile stimulation to determine the safety, feasibility, and optimization of GENUS as a potential therapy in the PD population.
Who can participate
Age range45 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject has Idiopathic PD defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor or rigidity and without any other known or suspected cause of Parkinsonism (according to Movement disorder society (MDS) clinical diagnostic criteria for Parkinson's disease confirmed by a fellowship trained movements disorder specialist
* Subject is Hoehn \& Yahr stage 2 to 3
* Subject has a Montreal Cognitive Assessment (MOCA) score ≥26.
* Subject is \> 45 and \<90 years of age.
* proficient in speaking, reading, and understanding English
* capable of providing informed written consent
* Subject is on a stable dose (at least 1 month prior to baseline visit) of antiparkinsonian agents and willing to remain on this dose for the duration of the study. If on a cholinesterase inhibitor, a stable dose without changes for 1 month is required.
* Subject has undergone a brain CT or MRI prior to rule out underlying structural lesions
Exclusion criteria:
* Subject has atypical Parkinson's syndrome(s) due to drugs, metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Lewy Body dementia)
* history of any psychiatric illness that would pose a safety risk
* diagnosis of dementia or other neurological conditions
* currently taking sedative medications that are clinically cont…
What they're measuring
1
Feasibility of gamma frequency stimulation
Timeframe: Immediately after completing the stimulation
2
Incidence of Stimulation-Related Adverse Events
Timeframe: Immediately after the completion of the stimulation